DONATE

Junior Communication Officer

Application Deadline: 20/12/2019
Ref: JCOT_GO
The Communications Unit is looking for a Junior Communication Officer to reinforce the international reputation of IBEC and provide support to European Projects coordinated by the Institute.
This position will be funded by H2020 European Union programme.

Postdoctoral researcher at Integrative Cell and tissue dynamics group


Application Deadline: 12/12/2019
Ref: PD-XT
The Integrative cell and tissue dyamics group at the Institute for Bioengineering of Catalonia (IBEC) is looking for Postdoctoral Researcher to work on the Mechanics of Intestinal Organoids. The contract will be within the framework of Mechanobiology, whose objective is to unveil the interplay between mechanics of biological function.

Elisabeth Engel en radio Euskadi

On the occasion of the annual meeting of the centres of excellence “Severo Ochoa and Maria de Maeztu” (SOMMa) at the 100xCiencia event, held in San Sebastián on November 22 and 23, Elisabeth Engel spoke on radio Euskadi about the intelligent devices they are developing in their laboratory. These bandages release nanoparticles containing calcium ions that are able to heal chronic lesions such as ulcers.

Joan Montero and colleagues in Boston suggest a new strategy for melanoma patients

IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.

Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.